Latest & greatest articles for acne

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on acne or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on acne and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Acne treatment and clinical papers

Acne is a common skin condition characterised by whiteheads (or blackheads), pimples and oily skin. It can lead to possible scarring. It is typically caused when hair follicles become inflamed and the sebaceous glands in the skin are overactive. The over production of sebum and a combination of dead skin cells and dirt can clog follicles and pores causing a break out. Acne can affect any age group but it’s more common in adolescents.

There are many ways to treat acne depending on the severity of the case. Treatments include a range of medications such as topical retinoids, antibiotics and in severe cases isotretinoin is prescribed. Research is ongoing to determine the side effects and harms caused by these drugs. Clinical trials and studies are vital to assess treatment.

The Trip Database has an extensive collection of articles on acne ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for acne

1. Oral isotretinoin for acne. (PubMed)

Oral isotretinoin for acne. BACKGROUND: Acne vulgaris, a chronic inflammatory disease of the pilosebaceous unit associated with socialisation and mental health problems, may affect more than 80% of teenagers. Isotretinoin is the only drug that targets all primary causal factors of acne; however, it may cause adverse effects. OBJECTIVES: To assess efficacy and safety of oral isotretinoin for acne vulgaris. SEARCH METHODS: We searched the following databases up to July 2017: the Cochrane Skin (...) : Randomised clinical trials (RCTs) of oral isotretinoin in participants with clinically diagnosed acne compared against placebo, any other systemic or topical active therapy, and itself in different formulation, doses, regimens, or course duration. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 31 RCTs, involving 3836 participants (12 to 55 years) with mild to severe acne. There were twice as many male participants as females.Most studies were

2018 Cochrane

2. Sarecycline (Seysara) - To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older

Sarecycline (Seysara) - To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older Drug Approval Package: Seysara (sarecycline) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Seysara (sarecycline) Company: Allergan, Inc. Application Number: 209521 Approval Date: 10/01/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA

2018 FDA - Drug Approval Package

3. Prevalence and psychological impact of Acne vulgaris among female secondary school students in Arar city, Saudi Arabia, in 2018 (PubMed)

Prevalence and psychological impact of Acne vulgaris among female secondary school students in Arar city, Saudi Arabia, in 2018 30214705 2018 11 14 2008-5842 10 8 2018 Aug Electronic physician Electron Physician Prevalence and psychological impact of Acne vulgaris among female secondary school students in Arar city, Saudi Arabia, in 2018. 7224-7229 10.19082/7224 Acne vulgaris is a common heath problem affecting adolescents with considerable impact on their quality of life. To determine (...) the prevalence of Acne vulgaris and its psychological impact among female secondary school students. A cross-sectional study was conducted during the period from January to March 2018, among all female secondary school students in 3 randomly selected schools, in Arar city (Saudi Arabia). The participants were clinically examined by a dermatologist to identify acne cases. Dermatological quality of life of acne cases were assessed using an Arabic version of Dermatology Life Quality Index (DLQI). Data collected

Full Text available with Trip Pro

2018 Electronic physician

4. Acne

Acne Top results for acne - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button (...) . An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for acne The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical

2018 Trip Latest and Greatest

5. Acne

Acne Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example

2018 Trip Evidence Maps

6. Safety and effectiveness of amoxicillin in the treatment of inflammatory acne (PubMed)

Safety and effectiveness of amoxicillin in the treatment of inflammatory acne 30175221 2018 11 14 2352-6475 4 3 2018 Sep International journal of women's dermatology Int J Womens Dermatol Safety and effectiveness of amoxicillin in the treatment of inflammatory acne. 174-175 10.1016/j.ijwd.2018.03.006 Acne is a common skin disease that predominantly affects teenagers and young adults. Systemic antibiotic therapy, including tetracyclines, macrolides, and trimethoprim-sulfamethoxazole (...) , is indicated in moderate-to-severe inflammatory disease. However, in certain cases, these antibiotics and other commonly prescribed treatments including oral contraceptives, spironolactone, and isotretinoin may be prohibited, especially in cases of pregnancy and drug intolerance. In this retrospective study, we assessed the safety and efficacy of systemic amoxicillin, which has a favorable tolerability profile and compatibility with pregnancy in the treatment of inflammatory acne. Guzman A K AK Division

Full Text available with Trip Pro

2018 International journal of women's dermatology

7. Acne vulgaris

Acne vulgaris Acne vulgaris - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Acne vulgaris Last reviewed: August 2018 Last updated: June 2018 Summary Acne may affect any age group, but it is most common in adolescents. Lesions consist of non-inflammatory comedones (whiteheads and blackheads) and inflammatory papules, pustules, nodules, and cysts. Systemic effects may be present with acne fulminans, a rare variant (...) of nodulocystic acne. Treatments include topical retinoids, keratolytics, and antibiotics; severe nodulocystic acne may require oral isotretinoin. Definition Acne vulgaris is a skin disease affecting the pilosebaceous unit. It is characterised by comedones, papules, pustules, nodules, cysts, and/or scarring, primarily on the face and trunk. Clinical manifestations range from mild comedonal acne to severe nodulocystic acne, which can be permanently disfiguring. In addition to the physical lesions, acne can

2018 BMJ Best Practice

10. Adalimumab (Humira) - hidradenitis suppurativa (acne inversa)

Adalimumab (Humira) - hidradenitis suppurativa (acne inversa) Final Appraisal Recommendation Advice No: 1217 – July 2017 Adalimumab (Humira ® ) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial) Limited submission by AbbVie Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3371), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal (...) – 1217: Adalimumab (Humira ® ) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial). July 2017 Recommendation of AWMSG Adalimumab (Humira ® ) is recommended as an option for use within NHS Wales for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic hidradenitis suppurativa (HS) therapy. This recommendation applies only in circumstances where the approved

2017 All Wales Medicines Strategy Group

11. Management of severe acne during pregnancy: A case report and review of the literature (PubMed)

Management of severe acne during pregnancy: A case report and review of the literature 28831424 2018 11 13 2352-6475 3 3 2017 Sep International journal of women's dermatology Int J Womens Dermatol Management of severe acne during pregnancy: A case report and review of the literature. 145-150 10.1016/j.ijwd.2017.06.001 The treatment of acne during pregnancy is often limited by the potential toxicities that are posed to the fetus by the most common and effective acne therapies. As with all (...) dermatoses during pregnancy, the treatment of acne vulgaris in this population requires a thorough understanding of the risks and benefits that are inherent to each treatment. We report on a case of a 30-year-old pregnant patient with severe acne conglobata who showed significant improvement with a combination treatment of topical modalities, oral metronidazole, and low dose prednisone during pregnancy. We also review the literature and present an approach for the care of these patients. Awan S Z SZ

Full Text available with Trip Pro

2017 International journal of women's dermatology

12. Adalimumab (Humira) - treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Adalimumab (Humira) - treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) Published 12 June 2017 Product Update: adalimumab (Humira ® ) 40mg/0.4mL pre-filled syringe and pre-filled pen adalimumab (Humira ® ) 40mg/0.8mL vial for paediatric use SMC No. (1243/17) AbbVie Ltd 05 May 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS (...) Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission adalimumab (Humira ® ) is accepted for use within NHS Scotland. Indication under review: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy. SMC has previously accepted adalimumab for the treatment of active moderate to severe HS (acne inversa) in adult patients with an inadequate

2017 Scottish Medicines Consortium

13. Dienogest/ethinylestradiol can be used for acne after certain other treatments have failed

Dienogest/ethinylestradiol can be used for acne after certain other treatments have failed European Medicines Agency - - Dienogest/ethinylestradiol can be used for acne after certain other treatments have failed Search for medicines Main navigation Dienogest/ethinylestradiol can be used for acne after certain other treatments have failed Press release 27/01/2017 Dienogest/ethinylestradiol can be used for acne after certain other treatments have failed Use should be limited to women who choose (...) oral contraception The European Medicines Agency (EMA) has recommended that medicines containing a combination of dienogest 2 mg and ethinylestradiol 0.03 mg can continue to be used to treat moderate acne when suitable treatments applied to the skin or antibiotics taken by mouth have not worked. However, these medicines, which are also approved as hormonal contraceptives, should only be used in women who choose oral contraception. Having evaluated the existing data on the effectiveness

2017 European Medicines Agency - EPARs

14. A Review of hormone-based therapies to treat adult acne vulgaris in women (PubMed)

A Review of hormone-based therapies to treat adult acne vulgaris in women 28492054 2018 11 13 2352-6475 3 1 2017 Mar International journal of women's dermatology Int J Womens Dermatol A Review of hormone-based therapies to treat adult acne vulgaris in women. 44-52 10.1016/j.ijwd.2017.02.018 Hormone-based therapies including combined oral contraceptive medications and spironolactone are considered effective therapies to treat adult acne in women. Our objective is to provide a concise (...) and comprehensive overview of the types of hormonal therapy that are available to treat acne and comment on their efficacy and safety profiles for clinical practice. A systematic search using the PubMed Database was conducted to yield 36 relevant studies for inclusion in the review and several conclusions were drawn from the literature. Treatment with oral contraceptive pills leads to significant reductions in lesion counts across all lesion types compared with placebo. There were no consistent differences

Full Text available with Trip Pro

2017 International journal of women's dermatology

15. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients (PubMed)

Spironolactone for the treatment of acne in women, a retrospective study of 110 patients 28560306 2018 11 13 2352-6475 3 2 2017 Jun International journal of women's dermatology Int J Womens Dermatol Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. 111-115 10.1016/j.ijwd.2016.12.002 There is limited evidence on the safety and efficacy of spironolactone in the treatment of women with acne. Thus, for many dermatologists spironolactone remains an alternative (...) rather than a mainstay treatment for female patients with acne. An electronic medical records search tool was used to select data from a group of women who received spironolactone to treat acne and were evaluated with the comprehensive acne severity scale (CASS) before treatment and at all follow-up visits. Data points were collected for CASS scores at each follow-up visit, concurrent and previous treatments, and side effects. These data points were used to draw conclusions about the safety

Full Text available with Trip Pro

2017 International journal of women's dermatology

19. Epiduo (adapalene/benzoyl peroxide) 0.3%/2.5% - acne vulgaris

Epiduo (adapalene/benzoyl peroxide) 0.3%/2.5% - acne vulgaris Epiduo® (adapalene/benzoyl peroxide) 0.3%/2.5% × Insert searchphrase to search the website Insert searchphrase to search the website > > > Epiduo® (adapalene/benzoyl peroxide) 0.3%/2.5% Conclusion Epiduo gel is approved for the treatment of acne vulgaris when comedones, several papules and pustules are present. Epiduo contains a combination of the active substances adapalene 3 mg/g (0.3%) and benzoyl peroxide 25 mg/g (2.5 (...) %) – in the following referred to as 0.3% A/BPO. Epiduo is also available in a lower strength containing adapalene 1 mg/g (0.1%) and benzoyl peroxide 25 mg/g (2.5%) – in the following referred to as 0.1% A/BPO. A statistically significant increase in efficacy has been observed in treatment with 0.3% A/BPO of patients with moderate to severe acne compared to inactive vehicle measured by improvement of acne and change in the number of inflammatory and non-inflammatory lesions. After 12 weeks’ treatment with 0.3

2017 Danish Pharmacotherapy Reviews

20. The age-old problem of acne (PubMed)

The age-old problem of acne 28560299 2018 11 13 2352-6475 3 2 2017 Jun International journal of women's dermatology Int J Womens Dermatol The age-old problem of acne. 71-76 10.1016/j.ijwd.2016.11.002 Acne vulgaris is one of the top three most commonly encountered dermatological problems worldwide in both primary and secondary care. Acne diagnosis and treatment date back to ancient Greek and Egyptian times. This article explores acne through the ages and discusses past theories on etiology (...) . 2008 Jun;98(6):1115-21 18445792 Science. 1953 May 15;117(3046):535-6 13056604 JAMA. 1969 Dec 15;210(11):2071-4 4243053 Yonsei Med J. 2009 Jun 30;50(3):445-7 19568610 Ulster Med J. 1944 Nov;13(2):109-22 20476317 N Engl J Med. 1979 Feb 15;300(7):329-33 153472 Acne History Pregnancy Retinoid Treatment 2016 08 19 2016 11 02 2016 11 02 2017 6 1 6 0 2017 6 1 6 0 2017 6 1 6 1 epublish 28560299 10.1016/j.ijwd.2016.11.002 S2352-6475(16)30028-4 PMC5440448

Full Text available with Trip Pro

2016 International journal of women's dermatology